ATE511401T1 - Kombinierte gentherapie zur behandlung makroskopischer glioma - Google Patents
Kombinierte gentherapie zur behandlung makroskopischer gliomaInfo
- Publication number
- ATE511401T1 ATE511401T1 AT05804343T AT05804343T ATE511401T1 AT E511401 T1 ATE511401 T1 AT E511401T1 AT 05804343 T AT05804343 T AT 05804343T AT 05804343 T AT05804343 T AT 05804343T AT E511401 T1 ATE511401 T1 AT E511401T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- glioma
- macroscopic
- gene therapy
- cancer
- Prior art date
Links
- 208000032612 Glial tumor Diseases 0.000 title 1
- 206010018338 Glioma Diseases 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 abstract 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 229940127073 nucleoside analogue Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60110004P | 2004-08-12 | 2004-08-12 | |
| PCT/US2005/028906 WO2006020949A2 (en) | 2004-08-12 | 2005-08-12 | Combined gene therapy for the treatment of macroscopic gliomas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE511401T1 true ATE511401T1 (de) | 2011-06-15 |
Family
ID=35908221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05804343T ATE511401T1 (de) | 2004-08-12 | 2005-08-12 | Kombinierte gentherapie zur behandlung makroskopischer glioma |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8420611B2 (de) |
| EP (2) | EP2338524B1 (de) |
| AT (1) | ATE511401T1 (de) |
| ES (1) | ES2364663T3 (de) |
| WO (1) | WO2006020949A2 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9924981D0 (en) | 1999-10-21 | 1999-12-22 | Univ Manchester | Gene therapy |
| EP2338524B1 (de) | 2004-08-12 | 2013-05-22 | Cedars-Sinai Medical Center | Kombinierte Gentherapie zur Behandlung makroskopischer Glioma |
| US8883493B2 (en) * | 2007-01-30 | 2014-11-11 | Cedars-Sinai Medical Center | Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene |
| WO2010047928A2 (en) * | 2008-10-24 | 2010-04-29 | Mount Sinai School Of Medicine Of New York University | Methods and compositions for treatment of fibrosis |
| WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| WO2016168862A1 (en) | 2015-04-17 | 2016-10-20 | Memorial Sloan-Kettering Cancer Center | Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors |
| MX2018010204A (es) | 2016-02-25 | 2019-05-06 | Memorial Sloan Kettering Cancer Center | Virus de la vaccinia atenuada competentes para replicacion con la supresion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer. |
| CN109152827B (zh) | 2016-02-25 | 2023-07-21 | 纪念斯隆凯特琳癌症中心 | 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途 |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US29227A (en) * | 1860-07-17 | Albert wild | ||
| US181870A (en) * | 1876-09-05 | Improvement in revolving garden and field hoes | ||
| US246038A (en) * | 1881-08-23 | Reflector | ||
| US31681A (en) * | 1861-03-12 | Puhchifg-machine | ||
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| CA2045129A1 (en) | 1989-02-01 | 1990-08-02 | Alfred I. Geller | Herpes simplex virus type i expression vector |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| AU8200191A (en) | 1990-07-09 | 1992-02-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5529774A (en) | 1991-08-13 | 1996-06-25 | The Regents Of The University Of California | In vivo transfer of the HSV-TK gene implanted retroviral producer cells |
| ES2197145T3 (es) | 1991-08-20 | 2004-01-01 | The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services | Transferencia de genes mediada por adenovirus al gastrointestinal. |
| US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
| US6630143B1 (en) | 1993-05-24 | 2003-10-07 | Immunex Corporation | Antibodies against flt3 ligand |
| US6080569A (en) | 1993-06-24 | 2000-06-27 | Merck & Co., Inc. | Adenovirus vectors generated from helper viruses and helper-dependent vectors |
| CA2167580A1 (en) * | 1993-07-22 | 1995-02-02 | Howard Y. Chen | Expression of human interleukin-1.beta. in a transgenic animal |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| JPH09505561A (ja) | 1993-10-01 | 1997-06-03 | アメリカ合衆国 | 神経系の遺伝子治療 |
| CA2173495A1 (en) | 1993-10-06 | 1995-04-13 | Kenneth W. Culver | Treatment of tumors by genetic transformation of tumor cells with genes encoding negative selective markers and cytokines |
| US5750398A (en) | 1993-11-30 | 1998-05-12 | David C. Johnson | Vector, element and method for inhibiting immune recognition |
| US6190655B1 (en) * | 1993-12-03 | 2001-02-20 | Immunex Corporation | Methods of using Flt-3 ligand for exogenous gene transfer |
| FR2725726B1 (fr) | 1994-10-17 | 1997-01-03 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en therapie genique |
| US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
| US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
| WO1996020733A1 (en) | 1995-01-04 | 1996-07-11 | Henry Ford Hospital | Treatment of tumors by transduction with negative selective markers, application of interaction agents and subsequent radiation exposure |
| FR2746016B1 (fr) | 1996-03-15 | 1998-04-17 | Combinaisons d'enzymes pour la destruction de cellules proliferatives | |
| US6030956A (en) | 1996-10-24 | 2000-02-29 | Boulikas; Teni | Combination gene therapy for human cancers |
| DE19648625A1 (de) | 1996-11-13 | 1998-05-14 | Soft Gene Gmbh | Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer |
| US6743631B1 (en) | 1998-03-17 | 2004-06-01 | North Shore University Hospital Research Corporation | Use of human serum resistant vector particles and cell lines for human gene therapy |
| US6291661B1 (en) | 1998-07-02 | 2001-09-18 | Immunex Corporation | flt3-L mutants and method of use |
| US6774119B1 (en) | 1999-04-26 | 2004-08-10 | Cedars-Sinai Medical Center | Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells |
| CA2375189C (en) | 1999-05-28 | 2010-02-09 | The Government Of The United States Of America | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| US6365394B1 (en) | 1999-09-29 | 2002-04-02 | The Trustees Of The University Of Pennsylvania | Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus |
| GB9924981D0 (en) | 1999-10-21 | 1999-12-22 | Univ Manchester | Gene therapy |
| GB2397063A (en) | 1999-10-21 | 2004-07-14 | Cedars Sinai Medical Center | A medicament comprising a cytotoxic pro drug activated by HSV TK |
| JP3857928B2 (ja) | 2001-02-08 | 2006-12-13 | 京セラ株式会社 | 金メッキ体の表面処理法及び表面処理物、金メッキ体の製造方法及び金メッキ体、並びに含硫黄分子の固定化法 |
| WO2002097137A1 (en) | 2001-05-29 | 2002-12-05 | The Regents Of The University Of California | Light controlled gene expression utilizing heterologous phytochromes |
| US7247297B2 (en) | 2001-09-14 | 2007-07-24 | The University Of Chicago | Use of DF3/MUC1 regulated expression in gene therapy |
| EP1539282A2 (de) | 2002-08-06 | 2005-06-15 | GenVec, Inc. | Verbessertes injektionssystem |
| EP2338524B1 (de) | 2004-08-12 | 2013-05-22 | Cedars-Sinai Medical Center | Kombinierte Gentherapie zur Behandlung makroskopischer Glioma |
| US8883493B2 (en) | 2007-01-30 | 2014-11-11 | Cedars-Sinai Medical Center | Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene |
-
2005
- 2005-08-12 EP EP11153885.6A patent/EP2338524B1/de active Active
- 2005-08-12 ES ES05804343T patent/ES2364663T3/es active Active
- 2005-08-12 WO PCT/US2005/028906 patent/WO2006020949A2/en active Application Filing
- 2005-08-12 AT AT05804343T patent/ATE511401T1/de not_active IP Right Cessation
- 2005-08-12 US US11/572,391 patent/US8420611B2/en active Active
- 2005-08-12 EP EP05804343A patent/EP1786474B1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1786474A2 (de) | 2007-05-23 |
| US8420611B2 (en) | 2013-04-16 |
| ES2364663T3 (es) | 2011-09-08 |
| EP1786474A4 (de) | 2008-11-19 |
| EP2338524B1 (de) | 2013-05-22 |
| EP1786474B1 (de) | 2011-06-01 |
| WO2006020949A3 (en) | 2006-09-14 |
| US20080181870A1 (en) | 2008-07-31 |
| EP2338524A1 (de) | 2011-06-29 |
| WO2006020949A2 (en) | 2006-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE511401T1 (de) | Kombinierte gentherapie zur behandlung makroskopischer glioma | |
| ATE540129T1 (de) | Target zur therapie kognitiver behinderungen | |
| EA200700427A1 (ru) | Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний | |
| CY1108927T1 (el) | Αναστολεις μιτωτικης κινεσινης | |
| MX2009006466A (es) | Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina. | |
| EA200700175A1 (ru) | Композиции и способы лечения воспалительных заболеваний | |
| DE60329990D1 (de) | Mitotische kinesin-hemmer | |
| DE60329756D1 (de) | Mitotische kinesin-hemmer | |
| DE602006018057D1 (de) | Substituierte chinolone und verwendungsverfahren | |
| ATE424388T1 (de) | Mitotische kinesinhemmer | |
| ATE447577T1 (de) | Mitotische kinesin-hemmer | |
| CY1112387T1 (el) | Θεραπευτικη συνθεση περιεχουσα τουλαχιστον ενα παραγωγο της πυρρολοβενζοδιαζεπινης και φλουδαραβινη | |
| ATE500319T1 (de) | Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden | |
| EP1766077A4 (de) | Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege | |
| IL181629A0 (en) | Compositions and methods for the diagnosis and tretment of tumor | |
| SI1615952T1 (sl) | Metoda zdravljenja vnetnih bolezni z uporabo specifičnih veznih sredstev humanega angiopoetin | |
| IL187343A0 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| ATE356804T1 (de) | Inhibitoren von mitotischem kinesin | |
| DE602005013811D1 (de) | Behandlung von fettsucht und verbundenen erkrankungen | |
| EA201001695A1 (ru) | Применение эпотилона d для лечения заболеваний, связанных с тау-белком | |
| NO20063368L (no) | Alfa-aminoamid-derivater anvendelige ved behandling av lidelser i nedre urinveier | |
| EA200601884A1 (ru) | Бета-карболины, применяемые для лечения воспалительных заболеваний | |
| MX2007010484A (es) | Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2. | |
| WO2004098612A3 (en) | Calcitriol analogs of uses thereof | |
| ATE478707T1 (de) | Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |